Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma
NCT03274258Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2018
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in renal medullary carcinoma (RMC), sponsored by University of Texas MD Anderson Cancer Center. Started May 2018; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
renal medullary carcinoma (RMC)
Beyond the preview
Go deeper on NCT03274258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274258.